References
- Vardiman J W, Brunning R D, Harris N L. WHO histological classification of chronic myeloproliferative diseases. World Health Organization Classification of Tumors: Tumours of the Haematopoietic and Lymphoid Tissues, E S Jaffe, N L Harris, H Stein, J W Vardiman. International Agency for Research on Cancer (IARC) Press, LyonFrance 2001; 17–44
- Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol 2005; 23: 8520–8530
- Tefferi A, Gilliland D G. The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis. Mayo Clin Proc 2005; 80: 947–958
- Tefferi A, Lasho T L, Schwager S M, Steensma D P, Mesa R A, Li C Y, et al. The JAK2 tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br J Haematol 2005; 131: 320–328
- Deeg H J, Gooley T A, Flowers M E, Sale G E, Slattery I T, Anasetti C, et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 2003; 102: 3912–3918
- Dupriez B, Morel P, Demory J L, Lai J L, Simmon M, Plantier I, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996; 88: 1013–1018
- Cervantes F, Pereira A, Esteve J, Rafel M, Cobo F, Rozman C, et al. Identification of ‘short-lived’ and ‘long-lived’ patients at presentation of idiopathic myelofibrosis. Br J Haematol 1997; 97: 635–640
- Okamura T, Kinukawa N, Niho Y, Mizoguchi H. Primary chronic myelofibrosis: clinical and prognostic evaluation in 336 Japanese patients. Int J Hematol 2001; 73: 194–198
- Dingli D, Schwager S M, Mesa R A, Li C -Y, Dewald G W, Tefferi A. Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis. Cancer 2006, in press
- Cervantes F, Barosi G, Demory J L, Reilly J, Guarnone R, Dupriez B, et al. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol 1998; 102: 684–690
- Reilly J T, Snowden J A, Spearing R L, Fitzgerald P M, Jones N, Watmore A, et al. Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases. Br J Haematol 1997; 98: 96–102
- Strasser-Weippl K, Steurer M, Kees M, Augustin F, Tzankov A, Dirnhofer S, et al. Age and hemoglobin level emerge as most important clinical prognostic parameters in patients with osteomyelofibrosis: introduction of a simplified prognostic score. Leuk Lymphoma 2006; 47: 441–450
- Dingli D, Schwager S M, Mesa R A, Li C -Y, Tefferi A. Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system. Cancer 2005, in press
- Tefferi A. New insights into the pathogenesis and drug treatment of myelofibrosis. Curr Opin Hematol 2006, in press
- Tefferi A, Dingli D, Li C Y, Dewald G W. Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia. Cancer 2005; 104: 1656–1660
- Silverstein M N. Agnogenic Myeloid Metaplasia, , et al. Publishing Science Group, Acton, MA 1975; 126
- Wolanskyj A P, Lasho T L, Schwager S M, McClure R F, Wadleigh M, Lee S J, et al. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol 2005; 131: 208–213
- Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005; 23: 2224–2232